![](https://www.ehc.eu/wp-content/uploads/jo-frame-2-260x145.png)
2018 and beyond: eliminating HCV from the haemophilia community, new EHC strategic plan and powerful advocacy tools
Eliminating HCV from the haemophilia community by 2022, new EHC strategic plan, projects we are working on….EHC NOW!
Eliminating HCV from the haemophilia community by 2022, new EHC strategic plan, projects we are working on….EHC NOW!
We have some exciting news…
The EHC December 2017 Newsletter is now out and can be accessed through the link below. This will be the last issue in its current form – from 2018, we welcome a more dynamic,...
Press Release Brussels – December 22nd 2017 Kedrion Biopharma, an Italian plasma-derived haemophilia treatment manufacturer, and Swedish Orphan Biovitrum AB (Sobi™), supplier of extended half-life (EHL) haemophilia treatment products, signed a Memorandum of Understanding...
As part of its continued efforts to improve the quality of life of people living with rare bleeding disorders in Europe, the European Haemophilia Consortium (EHC) officially launched the Procurement of Affordable Replacement Therapies...
As the two-year term of the first Inhibitor Working Group (IWG) is coming to an end, the EHC has launched a call for volunteers to join the team! The IWG coordinates the activities of...
The EHC is proud to announce the release of Inhibitor Stories, a documentary that captures the realities of life that people with haemophilia and inhibitors in Europe face day-to-day. Differences in access to treatment means very...
The European Haemophilia Consortium (EHC) has launched a survey to learn more about women with bleeding disorders and carriers in Europe. The survey, open until 5 November, aims to identify women with bleeding disorders...
The European Haemophilia Consortium (EHC) has launched a call for volunteers to join its newly established Committee for Women and Bleeding Disorders. The EHC Women and Bleeding Disorders Committee has been established to create...
Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes EMA concludes review of human factor VIII medicines authorised in EU The European Medicines Agency (EMA) has...